Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

1.4K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.4K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

1.2K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.2K
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

344
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
344
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

279
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
279
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

326
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
326
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

5.9K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence and comorbidities of double diabetes.

Diabetes research and clinical practice·2016
Same author

[Diabetes in old age--risk by over- and undertreatment].

MMW Fortschritte der Medizin·2013
Same author

[Hypertension in older patients].

MMW Fortschritte der Medizin·2013
Same author

Is there a benefit to use calculated percent body fat or age- and gender-adjusted BMI-SDS(LMS) to predict risk factors for cardiovascular disease? A German/Austrian multicenter DPV-Wiss analysis on 42 048 type 2 diabetic patients.

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association·2013
Same author

Type 2 diabetes from pediatric to geriatric age: analysis of gender and obesity among 120,183 patients from the German/Austrian DPV database.

European journal of endocrinology·2012
Same author

Multiple complications and frequent severe hypoglycaemia in 'elderly' and 'old' patients with Type 1 diabetes.

Diabetic medicine : a journal of the British Diabetic Association·2012

Related Experiment Video

Updated: Mar 22, 2026

Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People
12:59

Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People

Published on: July 5, 2017

13.3K

[Individualized diabetes therapy in older persons].

A Zeyfang1,2

  • 1AGAPLESION Bethesda Krankenhaus Stuttgart, Hohenheimerstr. 21, 70184, Stuttgart, Deutschland. andrej.zeyfang@bethesda-stuttgart.de.

Der Internist
|April 16, 2016
PubMed
Summary

Individualized diabetes therapy for older adults balances benefits and risks of medications like metformin, gliptins, and newer agents. Careful consideration of hypoglycemia risks is crucial for safe and effective treatment in this population.

Keywords:
ComorbidityDipeptidyl peptidase 4 inhibitorsGeriatric syndromesInsulinsMetformin

More Related Videos

Community-based Adapted Tango Dancing for Individuals with Parkinson's Disease and Older Adults
09:19

Community-based Adapted Tango Dancing for Individuals with Parkinson's Disease and Older Adults

Published on: December 9, 2014

26.4K

Related Experiment Videos

Last Updated: Mar 22, 2026

Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People
12:59

Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People

Published on: July 5, 2017

13.3K
Community-based Adapted Tango Dancing for Individuals with Parkinson's Disease and Older Adults
09:19

Community-based Adapted Tango Dancing for Individuals with Parkinson's Disease and Older Adults

Published on: December 9, 2014

26.4K

Area of Science:

  • Gerontology
  • Endocrinology
  • Pharmacology

Background:

  • Older adults with type 2 diabetes often present with multiple comorbidities, frailty, and functional limitations.
  • Polypharmacy is common and poses significant risks, particularly concerning antihyperglycemic agents and hypoglycemia.
  • Careful risk-benefit assessment is essential when prescribing diabetes medications to elderly patients.

Purpose of the Study:

  • To highlight the specific conditions and characteristics of older individuals with diabetes.
  • To emphasize the importance of individualized therapy approaches for diabetes management in the elderly.
  • To review current and novel therapeutic options for type 2 diabetes in older populations.

Main Methods:

  • Review of current literature on type 2 diabetes management in older adults.
  • Analysis of the advantages and disadvantages of various antidiabetic drug classes.
  • Discussion of individualized treatment strategies considering patient-specific factors.

Main Results:

  • Established oral agents like metformin and newer classes such as gliptins offer advantages for older patients.
  • Novel oral agents, including gliflozin drugs, present both benefits and drawbacks.
  • Injectable therapies, including glucagon-like peptide-1 (GLP-1) mimetics and modern insulins, can be valuable when used judiciously.

Conclusions:

  • Individualized therapy is paramount for managing type 2 diabetes in older adults.
  • A balanced approach considering efficacy, safety, and patient characteristics is necessary.
  • Metformin, gliptins, gliflozins, GLP-1 mimetics, and new insulins represent a spectrum of options for tailored diabetes care in the elderly.